CRNX Insider Trading
Crinetics Pharmaceuticals, Inc. | Pharmaceutical Preparations
Comprehensive Trading Performance Summary
The investment history of corporate insiders at Crinetics Pharmaceuticals, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-28 01:20 | 2023-12-26 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $35.89 | 3,000 | $107,670 | 79,298 | -3.6% |
| 2023-12-23 02:45 | 2023-12-21 | Pizzuti Dana | Officer - Chief Med and Dev Officer | OPT+S | $34.57 | 9,583 | $331,284 | 5,911 | 0.0% |
| 2023-12-14 00:44 | 2023-12-11 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $32.87 | 3,000 | $98,610 | 82,298 | -3.5% |
| 2023-11-30 00:31 | 2023-11-27 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $31.84 | 3,000 | $95,520 | 85,298 | -3.4% |
| 2023-11-07 02:02 | 2023-11-02 | Struthers Richard Scott | Director, Officer - President & CEO | OPT+S | $30.56 | 200,000 | $6,111,440 | 135,522 | 0.0% |
| 2023-11-04 02:38 | 2023-11-01 | Wilson Marc | Officer - CFO | OPT+S | $28.75 | 10,000 | $287,500 | 95,601 | 0.0% |
| 2023-10-20 00:01 | 2023-10-17 | Krasner Alan Seth | Officer - Chief Medical Officer | OPT+S | $30.00 | 7,000 | $210,000 | 43,210 | 0.0% |
| 2023-07-13 23:56 | 2023-07-11 | Struthers Richard Scott | Director, Officer - President & CEO | SELL | $20.21 | 50,000 | $1,010,315 | 630,805 | -7.3% |
| 2023-06-22 00:32 | 2023-06-20 | Wilson Marc | Officer - CFO | OPT+S | $19.97 | 30,922 | $617,404 | 95,158 | 0.0% |
| 2023-06-22 00:27 | 2023-06-16 | Struthers Richard Scott | Director, Officer - President & CEO | SELL | $20.81 | 50,000 | $1,040,500 | 680,805 | -6.8% |
| 2023-06-09 15:00 | 2023-06-08 | Vivaldi Coelho Rogerio | Director | BUY | $22.06 | 5,000 | $110,300 | 5,000 | +100.0% |
| 2023-04-06 02:12 | 2023-04-05 | Pizzuti Dana | Officer - Chief Development Officer | SELL | $16.15 | 8,212 | $132,624 | 4,500 | -64.6% |
| 2023-02-04 00:30 | 2023-02-01 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $19.59 | 3,126 | $61,238 | 64,689 | -4.6% |
| 2023-01-28 00:26 | 2023-01-25 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $21.07 | 8,336 | $175,640 | 67,815 | -10.9% |
| 2023-01-20 00:28 | 2023-01-17 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $18.00 | 3,126 | $56,268 | 76,151 | -3.9% |
| 2023-01-06 00:23 | 2023-01-03 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $18.35 | 3,126 | $57,362 | 79,277 | -3.8% |
| 2022-12-20 01:11 | 2022-12-15 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $16.00 | 3,126 | $50,016 | 82,403 | -3.7% |
| 2022-12-06 01:28 | 2022-12-01 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $17.84 | 3,126 | $55,768 | 84,968 | -3.5% |
| 2022-11-18 00:46 | 2022-11-15 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $18.72 | 3,126 | $58,519 | 88,094 | -3.4% |
| 2022-11-03 23:35 | 2022-11-01 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $18.52 | 3,126 | $57,894 | 91,220 | -3.3% |
| 2022-10-20 00:34 | 2022-10-17 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $17.73 | 3,126 | $55,424 | 94,346 | -3.2% |
| 2022-10-05 23:40 | 2022-10-03 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $19.64 | 3,126 | $61,395 | 97,472 | -3.1% |
| 2022-09-19 23:40 | 2022-09-15 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $21.01 | 4,168 | $87,570 | 100,598 | -4.0% |
| 2022-09-09 23:20 | 2022-09-07 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $21.00 | 1,042 | $21,884 | 104,766 | -1.0% |
| 2022-09-06 23:20 | 2022-09-01 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $18.59 | 3,126 | $58,112 | 105,808 | -2.9% |
| 2022-07-29 23:26 | 2022-07-26 | Knight Jeff E. | Officer - Chief Operating Officer | SELL | $20.70 | 1,152 | $23,847 | 4,950 | -18.9% |
| 2022-07-15 23:30 | 2022-07-13 | Fust Matthew K | Director | OPT+S | $20.96 | 5,700 | $119,455 | 12,536 | 0.0% |
| 2022-05-05 00:01 | 2022-05-02 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $20.10 | 3,247 | $65,252 | 107,598 | -2.9% |
| 2022-04-22 00:00 | 2022-04-18 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $25.81 | 5,664 | $146,188 | 110,845 | -4.9% |
| 2022-04-19 00:39 | 2022-04-18 | PERCEPTIVE ADVISORS LLC | 10% owner | BUY | $22.22 | 157,515 | $3,499,983 | 5,321,032 | +3.1% |
| 2022-04-16 01:00 | 2022-04-13 | Struthers Richard Scott | Director, Officer - President & CEO | SELL | $26.83 | 138,643 | $3,719,625 | 730,805 | -15.9% |
| 2022-04-08 00:58 | 2022-04-05 | Struthers Richard Scott | Director, Officer - President & CEO | SELL | $25.34 | 21,357 | $541,225 | 869,448 | -2.4% |
| 2022-04-07 02:08 | 2022-04-04 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $23.97 | 9,000 | $215,762 | 116,509 | -7.2% |
| 2022-04-02 00:39 | 2022-03-31 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $21.43 | 8,328 | $178,475 | 125,509 | -6.2% |
| 2022-03-17 23:33 | 2022-03-15 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $18.94 | 3,123 | $59,150 | 133,837 | -2.3% |
| 2022-03-03 05:00 | 2022-03-01 | Madan Ajay | Officer - Chief Development Officer | SELL | $19.88 | 9,000 | $178,920 | 176,995 | -4.8% |
| 2022-03-03 05:00 | 2022-03-01 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $19.73 | 3,123 | $61,617 | 136,960 | -2.2% |
| 2022-02-18 00:34 | 2022-02-15 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $18.64 | 3,123 | $58,213 | 123,583 | -2.5% |
| 2022-02-10 01:00 | 2022-02-07 | Madan Ajay | Officer - Chief Development Officer | SELL | $17.83 | 13,411 | $239,085 | 172,045 | -7.2% |
| 2022-02-04 00:30 | 2022-02-01 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $18.79 | 3,123 | $58,681 | 126,706 | -2.4% |
| 2022-01-22 00:54 | 2022-01-19 | Krasner Alan Seth | Officer - Chief Medical Officer | OPT+S | $21.21 | 6,700 | $142,080 | 8,311 | 0.0% |
| 2022-01-21 00:47 | 2022-01-18 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $23.29 | 4,168 | $97,073 | 128,875 | -3.1% |
| 2022-01-07 00:37 | 2022-01-03 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $28.02 | 7,168 | $200,847 | 133,043 | -5.1% |
| 2021-12-31 03:19 | 2021-12-28 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $27.95 | 3,000 | $83,852 | 140,211 | -2.1% |
| 2021-12-18 00:28 | 2021-12-15 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $24.14 | 5,668 | $136,826 | 143,211 | -3.8% |
| 2021-12-04 00:36 | 2021-12-01 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $27.38 | 5,668 | $155,190 | 148,879 | -3.7% |
| 2021-11-18 01:01 | 2021-11-15 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $27.01 | 7,168 | $193,574 | 154,547 | -4.4% |
| 2021-11-10 01:44 | 2021-11-05 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $28.06 | 16,500 | $463,041 | 161,715 | -9.3% |
| 2021-11-03 23:57 | 2021-11-01 | Betz Stephen F. | Officer - Chief Scientific Officer | SELL | $24.79 | 5,668 | $140,510 | 178,215 | -3.1% |
| 2021-11-03 23:55 | 2021-11-01 | Fust Matthew K | Director | OPT+S | $25.50 | 8,954 | $228,327 | 12,536 | 0.0% |
How to Interpret $CRNX Trades
Not every insider transaction in Crinetics Pharmaceuticals, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $CRNX shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for CRNX
Insider activity data for Crinetics Pharmaceuticals, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $CRNX, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.